DOP2019000215A - Anticuerpo humanizado para tratar o prevenir trastornos cognitivos, proceso para producirlo, y agente para tratar o prevenir trastornos cognitivos usándolo - Google Patents
Anticuerpo humanizado para tratar o prevenir trastornos cognitivos, proceso para producirlo, y agente para tratar o prevenir trastornos cognitivos usándoloInfo
- Publication number
- DOP2019000215A DOP2019000215A DO2019000215A DO2019000215A DOP2019000215A DO P2019000215 A DOP2019000215 A DO P2019000215A DO 2019000215 A DO2019000215 A DO 2019000215A DO 2019000215 A DO2019000215 A DO 2019000215A DO P2019000215 A DOP2019000215 A DO P2019000215A
- Authority
- DO
- Dominican Republic
- Prior art keywords
- treat
- cognitive disorders
- prevent cognitive
- humanized antibody
- agent
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/06—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies from serum
- C07K16/065—Purification, fragmentation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/40—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against enzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/44—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material not provided for elsewhere, e.g. haptens, metals, DNA, RNA, amino acids
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Immunology (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Biomedical Technology (AREA)
- Engineering & Computer Science (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmacology & Pharmacy (AREA)
- General Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Psychology (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2017035594A JP2018139530A (ja) | 2017-02-27 | 2017-02-27 | 認知症治療又は予防のためのヒト化抗体及びその製造方法、並びにそれを用いた認知症治療剤又は予防剤 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| DOP2019000215A true DOP2019000215A (es) | 2019-09-30 |
Family
ID=62025891
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DO2019000215A DOP2019000215A (es) | 2017-02-27 | 2019-08-15 | Anticuerpo humanizado para tratar o prevenir trastornos cognitivos, proceso para producirlo, y agente para tratar o prevenir trastornos cognitivos usándolo |
Country Status (27)
| Country | Link |
|---|---|
| US (3) | US10556950B2 (https=) |
| EP (1) | EP3585810B1 (https=) |
| JP (4) | JP2018139530A (https=) |
| KR (1) | KR102701634B1 (https=) |
| CN (2) | CN111320695B (https=) |
| AR (2) | AR110875A1 (https=) |
| AU (1) | AU2018224390C1 (https=) |
| BR (1) | BR112019016490A2 (https=) |
| CA (1) | CA3052538A1 (https=) |
| CL (3) | CL2019002296A1 (https=) |
| CO (1) | CO2019008786A2 (https=) |
| CR (1) | CR20190363A (https=) |
| DO (1) | DOP2019000215A (https=) |
| EA (1) | EA201991726A1 (https=) |
| ES (1) | ES3063126T3 (https=) |
| GE (2) | GEP20227392B (https=) |
| IL (1) | IL267945B2 (https=) |
| JO (1) | JOP20180014A1 (https=) |
| MA (1) | MA47608A (https=) |
| MX (2) | MX2019009945A (https=) |
| MY (1) | MY193821A (https=) |
| NI (1) | NI201900086A (https=) |
| PE (2) | PE20191614A1 (https=) |
| PH (1) | PH12019501929A1 (https=) |
| SG (2) | SG10201913419TA (https=) |
| TW (2) | TWI848904B (https=) |
| WO (2) | WO2018154392A1 (https=) |
Families Citing this family (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PL2857039T3 (pl) * | 2012-05-31 | 2020-05-18 | Osaka City University | Środek terapeutyczny lub środek profilaktyczny na otępienie |
| SG11201907422RA (en) | 2017-02-17 | 2019-09-27 | Denali Therapeutics Inc | Anti-tau antibodies and methods of use thereof |
| JP2018139530A (ja) | 2017-02-27 | 2018-09-13 | 帝人ファーマ株式会社 | 認知症治療又は予防のためのヒト化抗体及びその製造方法、並びにそれを用いた認知症治療剤又は予防剤 |
| AU2018352308B2 (en) | 2017-10-16 | 2025-06-05 | Eisai R&D Management Co., Ltd. | Anti-tau antibodies and uses thereof |
| US20210355199A1 (en) | 2018-06-28 | 2021-11-18 | University Of Virginia Patent Foundation | Compositions and methods for detecting and regulating fibronectin-integrin interaction and signaling |
| US12365724B2 (en) * | 2018-12-10 | 2025-07-22 | New York University | Antibodies binding to phospho-tau comprising phosphorylated Ser396 and Ser404 and methods of detecting thereof |
| US20220381790A1 (en) | 2019-02-11 | 2022-12-01 | University Of Virginia Patent Foundation | Selection and blockade of fertilization competent male and female gametes |
| EP3934677A4 (en) | 2019-03-13 | 2022-11-16 | University of Virginia Patent Foundation | COMPOSITIONS AND METHODS TO PROMOTE ISLAND VIABILITY AND INCREASE INSULINE SECRETION |
| JP7181438B2 (ja) * | 2019-08-06 | 2022-11-30 | アプリノイア セラピューティクス リミテッド | 病理学的タウ種に結合する抗体及びその使用 |
| CN115605594A (zh) * | 2020-06-02 | 2023-01-13 | 帝人制药株式会社（Jp） | 抗igf-1受体人源化抗体 |
| CA3183835A1 (en) * | 2020-06-25 | 2021-12-30 | Jeanne E. Baker | High affinity antibodies targeting tau phosphorylated at serine 413 |
| US20250034559A1 (en) | 2021-11-17 | 2025-01-30 | Voyager Therapeutics, Inc. | Compositions and methods for the treatment of tau-related disorders |
| CN115322255B (zh) * | 2022-04-25 | 2025-03-07 | 上海药明生物医药有限公司 | 一种优化的Fc变体及其应用 |
| KR20250069606A (ko) | 2022-09-15 | 2025-05-19 | 보이저 테라퓨틱스, 인크. | 타우 결합 화합물 |
| WO2025122634A1 (en) | 2023-12-05 | 2025-06-12 | Voyager Therapeutics, Inc. | Compositions and methods for the treatment of tau-related disorders |
| WO2025207501A1 (en) * | 2024-03-26 | 2025-10-02 | Merck Sharp & Dohme Llc | Crystals of anti-human tau monoclonal antibody |
| CN119080924B (zh) * | 2024-07-04 | 2025-02-25 | 上海交通大学医学院附属第九人民医院 | 一种单克隆免疫球蛋白及其用途 |
Family Cites Families (26)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS587390B2 (ja) | 1975-03-11 | 1983-02-09 | ツキシマキカイ カブシキガイシヤ | ア−クヨウセツホウホウ |
| US5530101A (en) | 1988-12-28 | 1996-06-25 | Protein Design Labs, Inc. | Humanized immunoglobulins |
| US5859205A (en) | 1989-12-21 | 1999-01-12 | Celltech Limited | Humanised antibodies |
| EP1400536A1 (en) | 1991-06-14 | 2004-03-24 | Genentech Inc. | Method for making humanized antibodies |
| WO1994004679A1 (en) | 1991-06-14 | 1994-03-03 | Genentech, Inc. | Method for making humanized antibodies |
| JP3587390B2 (ja) | 1994-03-17 | 2004-11-10 | タカラバイオ株式会社 | リン酸化アミノ酸誘導体及びリン酸化ペプチド合成方法 |
| JP4754352B2 (ja) | 2003-08-29 | 2011-08-24 | 株式会社リバース・プロテオミクス研究所 | タンパク質の固定化方法 |
| AU2004297616B2 (en) | 2003-12-04 | 2008-12-18 | Xencor, Inc. | Methods of generating variant proteins with increased host string content and compositions thereof |
| UA107571C2 (xx) | 2009-04-03 | 2015-01-26 | Фармацевтична композиція | |
| US8609097B2 (en) | 2009-06-10 | 2013-12-17 | Hoffmann-La Roche Inc. | Use of an anti-Tau pS422 antibody for the treatment of brain diseases |
| MY164376A (en) | 2010-10-07 | 2017-12-15 | Univ Leuven Kath | Phosphospecific antibodies recognizing tau |
| CA2813493C (en) | 2010-10-11 | 2019-07-09 | University Of Zurich | Human anti-tau antibodies |
| MX350311B (es) | 2011-12-20 | 2017-09-01 | Janssen Biotech Inc | Anticuerpos anti-phf-tau y sus usos. |
| PL2857039T3 (pl) * | 2012-05-31 | 2020-05-18 | Osaka City University | Środek terapeutyczny lub środek profilaktyczny na otępienie |
| NZ630542A (en) * | 2012-08-16 | 2017-06-30 | Ipierian Inc | Methods of treating a tauopathy |
| CA2896066C (en) | 2012-12-21 | 2022-07-12 | Biogen Ma Inc. | Human anti-tau antibodies |
| BR112015030356A2 (pt) | 2013-06-10 | 2017-12-05 | Ipierian Inc | métodos de tratamento de uma taupatia |
| AU2014368696A1 (en) | 2013-12-20 | 2016-06-02 | F. Hoffmann-La Roche Ag | Humanized anti-Tau(pS422) antibodies and methods of use |
| AR100978A1 (es) * | 2014-06-26 | 2016-11-16 | Hoffmann La Roche | LANZADERAS CEREBRALES DE ANTICUERPO HUMANIZADO ANTI-Tau(pS422) Y USOS DE LAS MISMAS |
| TWI734975B (zh) * | 2014-06-27 | 2021-08-01 | 美商Ｃ２Ｎ醫療診斷有限責任公司 | 人類化抗-tau抗體 |
| CA2961439A1 (en) | 2014-11-05 | 2016-05-12 | Genentech, Inc. | Anti-fgfr2/3 antibodies and methods using same |
| WO2016112078A2 (en) | 2015-01-08 | 2016-07-14 | Janssen Biotech, Inc. | Anti-phf-tau antibodies and their uses |
| US10344081B2 (en) | 2015-07-06 | 2019-07-09 | Ucb Biopharma Sprl | Tau-binding antibodies |
| WO2017005734A1 (en) | 2015-07-06 | 2017-01-12 | Ucb Biopharma Sprl | Tau-binding antibodies |
| JO3711B1 (ar) | 2015-07-13 | 2021-01-31 | H Lundbeck As | أجسام مضادة محددة لبروتين تاو وطرق استعمالها |
| JP2018139530A (ja) | 2017-02-27 | 2018-09-13 | 帝人ファーマ株式会社 | 認知症治療又は予防のためのヒト化抗体及びその製造方法、並びにそれを用いた認知症治療剤又は予防剤 |
-
2017
- 2017-02-27 JP JP2017035594A patent/JP2018139530A/ja active Pending
-
2018
- 2018-02-25 WO PCT/IB2018/000267 patent/WO2018154392A1/en not_active Ceased
- 2018-02-26 TW TW107106444A patent/TWI848904B/zh active
- 2018-02-26 TW TW113125487A patent/TW202506718A/zh unknown
- 2018-02-27 KR KR1020197024146A patent/KR102701634B1/ko active Active
- 2018-02-27 MY MYPI2019004787A patent/MY193821A/en unknown
- 2018-02-27 AR ARP180100454A patent/AR110875A1/es unknown
- 2018-02-27 MA MA047608A patent/MA47608A/fr unknown
- 2018-02-27 CR CR20190363A patent/CR20190363A/es unknown
- 2018-02-27 PE PE2019001541A patent/PE20191614A1/es unknown
- 2018-02-27 US US15/906,773 patent/US10556950B2/en active Active
- 2018-02-27 JO JOP/2018/0014A patent/JOP20180014A1/ar unknown
- 2018-02-27 BR BR112019016490A patent/BR112019016490A2/pt unknown
- 2018-02-27 IL IL267945A patent/IL267945B2/en unknown
- 2018-02-27 SG SG10201913419TA patent/SG10201913419TA/en unknown
- 2018-02-27 WO PCT/IB2018/000249 patent/WO2018154390A1/en not_active Ceased
- 2018-02-27 JP JP2019545918A patent/JP7165996B2/ja active Active
- 2018-02-27 AU AU2018224390A patent/AU2018224390C1/en active Active
- 2018-02-27 PE PE2024001024A patent/PE20241514A1/es unknown
- 2018-02-27 ES ES18718907T patent/ES3063126T3/es active Active
- 2018-02-27 GE GEAP201815170A patent/GEP20227392B/en unknown
- 2018-02-27 CN CN202010117151.0A patent/CN111320695B/zh active Active
- 2018-02-27 SG SG11201907548PA patent/SG11201907548PA/en unknown
- 2018-02-27 CN CN201880008302.XA patent/CN110382528A/zh active Pending
- 2018-02-27 EP EP18718907.1A patent/EP3585810B1/en active Active
- 2018-02-27 MX MX2019009945A patent/MX2019009945A/es unknown
- 2018-02-27 EA EA201991726A patent/EA201991726A1/ru unknown
- 2018-02-27 CA CA3052538A patent/CA3052538A1/en active Pending
- 2018-02-27 GE GEAP202215170A patent/GEAP202215170A/en unknown
-
2019
- 2019-08-09 NI NI201900086A patent/NI201900086A/es unknown
- 2019-08-13 CO CONC2019/0008786A patent/CO2019008786A2/es unknown
- 2019-08-13 CL CL2019002296A patent/CL2019002296A1/es unknown
- 2019-08-15 DO DO2019000215A patent/DOP2019000215A/es unknown
- 2019-08-20 MX MX2023013246A patent/MX2023013246A/es unknown
- 2019-08-20 PH PH12019501929A patent/PH12019501929A1/en unknown
- 2019-08-22 AR ARP190102386A patent/AR117952A2/es unknown
-
2020
- 2020-01-17 US US16/746,725 patent/US10894829B2/en active Active
- 2020-12-15 US US17/122,325 patent/US11739143B2/en active Active
-
2021
- 2021-09-13 CL CL2021002389A patent/CL2021002389A1/es unknown
-
2022
- 2022-10-18 JP JP2022166859A patent/JP2023002670A/ja active Pending
-
2024
- 2024-02-02 CL CL2024000339A patent/CL2024000339A1/es unknown
- 2024-08-28 JP JP2024146101A patent/JP2024170459A/ja active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DOP2019000215A (es) | Anticuerpo humanizado para tratar o prevenir trastornos cognitivos, proceso para producirlo, y agente para tratar o prevenir trastornos cognitivos usándolo | |
| CL2019001411A1 (es) | Métodos para inhibición de la fibrosis en un sujeto en necesidad de ellos. (divisional solicitud 201801817) | |
| CL2019003114A1 (es) | Anticuerpos anti–tau y métodos de uso (divisional solicitud 201703063) | |
| CL2020001391A1 (es) | Formulación liofilizada de un anticuerpo monoclonal contra la transtirretina. | |
| ECSP21025707A (es) | Anticuerpos estabilizadores de trem2 | |
| CL2018002694A1 (es) | Moleculas de anticuerpos que se unen a lag-3 y usos de las mismas (divisional solicitud 201602112) | |
| EA201991862A1 (ru) | Композиции и способы, предназначенные для лечения гемоглобинопатий | |
| UY37779A (es) | Moléculas de anticuerpo que se unen a cd73 y usos de las mismas | |
| BR112019002331A2 (pt) | anticorpos anti-siglec-7 para o tratamento do câncer e métodos para obtenção dos mesmos | |
| CR20190271A (es) | Anticuerpos antitau y métodos de uso | |
| MX2018009325A (es) | Compuestos y metodos para tratar enfermedades mediadas por el acido ribonucleico (arn). | |
| EA201890394A1 (ru) | КОМПОЗИЦИИ НА ОСНОВЕ iRNA ДЛЯ ТРАНСТИРЕТИНА (TTR) И СПОСОБЫ ИХ ПРИМЕНЕНИЯ ДЛЯ ЛЕЧЕНИЯ ИЛИ ПРЕДУПРЕЖДЕНИЯ АССОЦИИРОВАННЫХ С TTR ЗАБОЛЕВАНИЙ | |
| MX2022010229A (es) | Composicion para profilaxis o tratamiento de enfermedades relacionadas con interleucina 8 (il-8). | |
| EA201791773A1 (ru) | Цистеиновая протеаза | |
| MX394170B (es) | Anticuerpos anti-transtiretina | |
| EA201990400A1 (ru) | Соединения и композиции и их применение | |
| JOP20210050A1 (ar) | معدلات تعبير pnpla3 | |
| EA202090814A1 (ru) | Способы и композиции для лечения буллезного эпидермолиза | |
| MX2019011423A (es) | Metodos de tratamiento de enfermedades neurodegenerativas. | |
| EA201990864A1 (ru) | Конструкции для экспрессии фратаксина | |
| MX2019010060A (es) | Composiciones y metodo para tratar cancer. | |
| BR112018012126A2 (pt) | ?adjuvante, método para prevenir e/ou tratar uma doença autoimune, e, uso de um adjuvante? | |
| MX391162B (es) | Anticuerpos altamente potentes que se unen a receptor de muerte 4 y receptor de muerte 5 | |
| EA202090330A1 (ru) | Композиции и способы лечения расстройств, связанных со стрессом | |
| EA202090891A1 (ru) | Молекулы антител против cd138 и их применение |